Maturity-onset diabetes of the young (MODY)
MODY · Endocrine
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
Monogenic autosomal dominant diabetes presenting in young, often non-obese people with a strong family history and preserved beta-cell function. Correct diagnosis changes treatment dramatically, often allowing sulfonylureas or no treatment.
Red flags
- Ketosis or rapid deterioration (reconsider type 1 diabetes)
- Pregnancy with GCK-MODY (fetal genotype guides maternal treatment)
- Severe hyperglycaemia unresponsive to sulfonylurea
Assessment
Differential diagnosis
- Type 1 diabetes
- Type 2 diabetes
- Neonatal diabetes
- Latent autoimmune diabetes of adults
- Secondary diabetes
Investigations
- GAD and islet autoantibodies (negative in MODY)
- C-peptide (detectable/preserved outside honeymoon)
- Genetic testing (HNF1A, HNF4A, GCK and others)
- Fasting glucose and HbA1c
- MODY probability calculator to guide testing
Management
- Suspect MODY in antibody-negative, C-peptide-positive young diabetics with a multigenerational family history
- Use clinical features and the MODY probability model to select candidates
- Send targeted genetic panel for common subtypes
- GCK-MODY: stop treatment (mild stable fasting hyperglycaemia, no complications) except in pregnancy
- HNF1A/HNF4A-MODY: use low-dose sulfonylurea as first-line, highly effective therapy
- Transition patients mislabelled as type 1 off insulin where appropriate and safe
- Screen first-degree relatives and offer predictive testing
- Counsel on 50% inheritance risk and implications for pregnancy
- Arrange complication surveillance for subtypes with microvascular risk
Drugs & doses
Gliclazide 20-40 mg PO once daily (low dose, HNF1A/HNF4A)
No pharmacotherapy for most GCK-MODY
Insulin only if sulfonylurea inadequate or in pregnancy as needed
Disposition
Refer to a specialist/genetics-linked diabetes service for confirmatory testing, family cascade screening and treatment reassignment.
Complications & pitfalls
- Inappropriate lifelong insulin if misdiagnosed as type 1
- Microvascular complications in HNF1A/HNF4A if poorly controlled
- Macrosomia/fetal growth effects in GCK pregnancies
- Hypoglycaemia if sulfonylurea overdosed
Exam pearls
- Antibody-negative, C-peptide-positive diabetes diagnosed before 35 with strong family history should prompt MODY testing
- GCK-MODY needs no treatment and carries no excess complication risk outside pregnancy
- HNF1A-MODY patients are exquisitely sensitive to low-dose sulfonylureas
- A correct genetic diagnosis can free a patient from insulin for life
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.